WO1998027968A1 - Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain - Google Patents
Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain Download PDFInfo
- Publication number
- WO1998027968A1 WO1998027968A1 PCT/US1997/022826 US9722826W WO9827968A1 WO 1998027968 A1 WO1998027968 A1 WO 1998027968A1 US 9722826 W US9722826 W US 9722826W WO 9827968 A1 WO9827968 A1 WO 9827968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- inflammatory drug
- composition
- inflammatory
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- the present invention is directed to a topical formulation containing an anti-inflammatory drug in an effective amount and which allows said anti -inflammatory to penetrate the skin.
- Soft-tissue pain and swelling associated with arthritis have been successfully treated by the administration of oral nonsteroidal anti -inflammatory drugs, such a indomethacin and aspirin.
- nonsteroidal anti -inflammatory drugs such as indomethacin and aspirin.
- the basis of treatment with nonsteroidal anti -inflammatory drugs is the inhibition of other products of synthetic pathway or prostaglandin.
- nonsteroidal drugs for arthritis is usually in doses higher than for analgesic use.
- nonsteroidal drugs at therapeutic effective doses can cause severe side effects particularly of the GI system.
- aspirin probably the most commonly used drug, at concentrations necessary to treat the inflammation associated with rheumatoid arthritis, can cause hearing loss, bleeding ulcers and increased coagulation time.
- Fenoprofen can cause renal disorders in addition to GI problems.
- Phenylbutazone can cause edema and hematological complications in addition to GI problems.
- Indomethacin causes gastrointestinal bleeding, and exacerbation of renal insufficiency when administered in doses necessary to reach therapeutic concentrations at the site of action.
- nonsteroidal anti -inflammatory agents for the topical administration.
- the present invention is predicated on the discovery that formulations of indomethacin, a nonsteroidal, in one or a mixture of organic solvents and which include benzyl alcohol enhance penetration allowing the drug to concentrate in the skin and underlying tissues, i.e., muscle and cartilage, to a greater extent and remain for a longer period of time than when the drug is administered orally.
- the specific formulations are comprised of a nonsteroidal drug in a therapeutic sufficient amount dissolved in a carrier system made up of a first solvent phase of a relatively high boiling solvent (e.g., benzyl alcohol) which acts to enhance dermal penetration, and a second solvent phase of a low boiling solvent (e.g. isopropyl alcohol). Both solvents are compatible and co-soluble in each other and of a type in which the nonsteroidal drug can be dissolved. When applied topically, the low boiling solvent will quickly dissipate due to the patient's temperature leaving a concentrated solution of the nonsteroidal drug in the remaining high boiling solvent which enhances penetration through the skin.
- a carrier system made up of a first solvent phase of a relatively high boiling solvent (e.g., benzyl alcohol) which acts to enhance dermal penetration, and a second solvent phase of a low boiling solvent (e.g. isopropyl alcohol).
- a relatively high boiling solvent e.g., benzyl alcohol
- a low boiling solvent
- the methods and compositions of the present invention are intended for treatment of soft tissue pains associated with arthritis and other localized inflammatory events of a patient, particularly human patients, but including other mammalian hosts.
- Arthritis is a term that embraces a group of diseases characterized by pain and swelling particularly of the joints, which causes various levels of discomfort and disability; in many cases the underlying causes are poorly understood.
- the curative effects of oral nonsteroidal anti- inflammatory drugs for arthritic and other soft tissue pains are well documented.
- compositions of the present invention rely on administering a nonsteroidal anti-inflammatory drug, alone or a combination with one or more nonsteroidal anti-inflammatory drug in a concentration of 0.5 to 10%, in a vehicle containing benzyl alcohol in a concentration from 0.5 to 10%, and one or more solvent of low boiling point, such as acetone, isopropyl alcohol, ethyl alcohol.
- the formulation can contain various inactive ingredients to make the formulation in the form of a cream or gel .
- compositions of this invention are exemplary of the compositions of this invention. These formulations are illustrative only and are not intended to limit the scope of this invention and should not be so construed.
- a solution for topically treating topically soft tissue pain is prepared as follows :
- Formula 2 A solution as described in Formula 1 except that a different nonsteroidal anti -inflammatory drug is used, such as indomethacin, ibuprofen, tol etin, phenylbutazone, ketoprofen, etc.
- Formula 3 A gel for the topical treatment of soft tissue pain is prepared as follows:
- Formula 4 A gel as described in Formula 3 except that a different nonsteroidal anti -inflammatory drug is used, such as indomethacin, ibuprofen, tolmetin, phenylbutazone, ketoprofen, etc.
- a different nonsteroidal anti -inflammatory drug such as indomethacin, ibuprofen, tolmetin, phenylbutazone, ketoprofen, etc.
- a cream for the topical treatment of soft tissue pain is prepared as follows:
- a different nonsteroidal anti -inflammatory drug such as indomethacin, ibuprofen, tolmetin, phenylbutazone, ketoprofen, or other nonsteroidal anti -inflammatory drug, or a combination of nonsteroidal anti -inflammatory drugs.
Abstract
The present invention is directed to a topical formulation containing benzyl alcohol as a penetration enhancer and an anti-inflammatory drug in an effective amount and which allows said anti-inflammatory to penetrate the skin.
Description
NOVEL TOPICAL FORMULATION OF ANTI-INFLAMMATORY DRUGS FOR THE TREATMENT OF LOCALIZED PAIN
FIELD OF THE INVENTION The present invention is directed to a topical formulation containing an anti-inflammatory drug in an effective amount and which allows said anti -inflammatory to penetrate the skin.
BACKGROUND OF THE INVENTION There are many type of arthritis that have in common the same expression of symptoms, namely joint and soft tissue pain and restricted joint movement. Arthritic conditions are characterized by inflammation and tissue damage to the joints. The pathogenesis of arthritis is incompletely understood; however, the immune system is involved in producing inflammation and local tissue damage. The inflammatory process is mediated by a variety of endogenous chemicals, among which are histamine, serotonin, constituents of the complement system, bradykinin and prostaglandin. Prostaglandin levels are increased in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis, and prostaglandin E2 has been shown to degrade articular cartilage.
Soft-tissue pain and swelling associated with arthritis have been successfully treated by the administration of oral nonsteroidal anti -inflammatory drugs, such a indomethacin and aspirin. The basis of treatment with nonsteroidal anti -inflammatory drugs is the inhibition of other products of synthetic pathway or prostaglandin.
The administration of nonsteroidal drugs for arthritis is usually in doses higher than for analgesic use. Unfortunately nonsteroidal drugs at therapeutic effective doses can cause severe side effects particularly of the GI system. In addition aspirin, probably the most commonly used drug, at concentrations necessary to treat the inflammation associated with rheumatoid arthritis, can cause hearing loss, bleeding ulcers and increased coagulation time. Fenoprofen can cause renal disorders in addition to GI problems. Phenylbutazone can cause edema and hematological complications in addition to GI problems. Indomethacin causes gastrointestinal
bleeding, and exacerbation of renal insufficiency when administered in doses necessary to reach therapeutic concentrations at the site of action.
Because of the complications associated with the oral use of nonsteroidal drugs, it would be of great value to have a topical preparation of nonsteroidal that would deliver therapeutic effective doses of the drug locally. Many investigators have discovered compounds that enhance penetration of co-administered compounds through the stratum corneum of the skin. A number of compounds, such a piperidone, pyrrolidone, oleic acid, cetyl lactate, propylene glycol, have been used to aid in the passage of nonsteroidal anti- inflammatory drugs across the stratum corneum. For indomethacin it has been shown that topical and oral administration have equal efficacy in a rat model. Limited clinical studies have demonstrated some efficacy for topical formulation of felbinac, piroxicam, ibuprofen and indomethacin. However, no topical, effective preparation of topical nonsteroidal anti -inflammatory drugs is available in the United States.
Therefore, it would be desirable to provide an effective topical preparation of nonsteroidal anti -inflammatory drugs for the treatment of localized pain and swelling, particularly where such drug preparations have fewer side effects when compared with the same drug administered orally. Such formulations should be safe, have fewer side effects and results in therapeutic concentrations at the tissue site of action. The use of topical nonsteroidal anti- inflammatory agents for the treatment of pain and swelling is suggested and/or described in U.S. Patent No. 4,482,539 which describes a water-based topical cream containing betamethasone dipropionate for treating dermatological disorders; U.S. Patent No. 4,553,546, U.S. Patent No. 4,540,572 which describes a water-based gel-like ointment containing indomethacin; U.S. patent No. 4,670,254 containing diclofenac sodium and U.S. patent No. 4,917,886 which describes a general formulation for the preparation of a topically administrable nonsteroidal drug. All of the above formulation are water-based, limiting penetration through the skin.
SUMMARY OF THE INVENTION
Novel methods of formulating nonsteroidal anti -inflammatory agents for the topical administration have been discovered. The present invention is predicated on the discovery that formulations of indomethacin, a nonsteroidal, in one or a mixture of organic solvents and which include benzyl alcohol enhance penetration allowing the drug to concentrate in the skin and underlying tissues, i.e., muscle and cartilage, to a greater extent and remain for a longer period of time than when the drug is administered orally. The specific formulations are comprised of a nonsteroidal drug in a therapeutic sufficient amount dissolved in a carrier system made up of a first solvent phase of a relatively high boiling solvent (e.g., benzyl alcohol) which acts to enhance dermal penetration, and a second solvent phase of a low boiling solvent (e.g. isopropyl alcohol). Both solvents are compatible and co-soluble in each other and of a type in which the nonsteroidal drug can be dissolved. When applied topically, the low boiling solvent will quickly dissipate due to the patient's temperature leaving a concentrated solution of the nonsteroidal drug in the remaining high boiling solvent which enhances penetration through the skin.
As an example of an anti -inflammatory drug, we have prepare 1% formulations of indomethacin in propylene glycol/isopropyl alcohol (PG/EtOH) and in benzyl alcohol, acetone and isopropyl alcohol in a ration of 1:4:5 (BAIA) . We have studied transdermal penetration of the two formulations and compared the levels of drug in various tissues following oral administration and transdermal administration using the two topical formulations we prepared. Table 1 shows the concentration of indomethacin in various tissues 4 hours following topical administration in PG/EtOH BAIA or oral administration of the same amount of indomethacin containing 2 μCi of 2- C-indomethacin.
TABLE 1
Concentration of Indomethacin in various rat tissues 4 hours following administration of Indomethacin
Tissue CPM/mg tissue
BAIA PG/EtOH Oral
Skin 843 245 17
Deltoid 75 19 19
Capsule 30 18 19
Liver 5 7 9
Kidney 3 3 8
Blood 4 9
Urine 19 37 167
Feces 3 2 4
This pattern of distribution remains for at least eight hours following administration, with the exception that the amount of indomethacin in the feces increases markedly after oral administration, but not after topical administration. The data clearly demonstrates that topical administration in BAIA results in an increased concentration in the subcutaneous tissues than topical administration in PG/EtOH or oral administration.
Preliminary clinical studies with a 4% diclofenac solution and a 4% indomethacin solution have shown that these formulation are effective in relieve soft tissue pain associated with arthritic conditions .
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The methods and compositions of the present invention are intended for treatment of soft tissue pains associated with arthritis
and other localized inflammatory events of a patient, particularly human patients, but including other mammalian hosts. Arthritis is a term that embraces a group of diseases characterized by pain and swelling particularly of the joints, which causes various levels of discomfort and disability; in many cases the underlying causes are poorly understood. The curative effects of oral nonsteroidal anti- inflammatory drugs for arthritic and other soft tissue pains are well documented.
The methods and compositions of the present invention rely on administering a nonsteroidal anti-inflammatory drug, alone or a combination with one or more nonsteroidal anti-inflammatory drug in a concentration of 0.5 to 10%, in a vehicle containing benzyl alcohol in a concentration from 0.5 to 10%, and one or more solvent of low boiling point, such as acetone, isopropyl alcohol, ethyl alcohol. In addition, the formulation can contain various inactive ingredients to make the formulation in the form of a cream or gel .
The following formulations are exemplary of the compositions of this invention. These formulations are illustrative only and are not intended to limit the scope of this invention and should not be so construed.
Formula 1
A solution for topically treating topically soft tissue pain is prepared as follows :
Component Amount
Diclofenac 100 mg to 10 g
Benzyl alcohol 2 to 10 ml
Acetone 30 to 40 ml Isopropyl alcohol to 100 ml
Formula 2 A solution as described in Formula 1 except that a different nonsteroidal anti -inflammatory drug is used, such as indomethacin, ibuprofen, tol etin, phenylbutazone, ketoprofen, etc.
Formula 3 A gel for the topical treatment of soft tissue pain is prepared as follows:
Component Amount Diclofenac 100 mg to 10 g
Benzyl Alcohol 2 to 10 ml
Acetone 30 to 40 ml
Carbomer 940 5 to 10 g
Propylene glycol 2 to 10 g Total 100 ml
Formula 4 A gel as described in Formula 3 except that a different nonsteroidal anti -inflammatory drug is used, such as indomethacin, ibuprofen, tolmetin, phenylbutazone, ketoprofen, etc.
Formula 5
A cream for the topical treatment of soft tissue pain is prepared as follows:
Component Amount
Diclofenac 100 mg to 10 g
Benzyl alcohol 2 to 10 ml isopropyl myristate 5 to 15 g polyoxyl 40 stearate 5 to 20 g distilled water to 100 ml
Formula 6
A cream as described in Formula 5 except that a different nonsteroidal anti -inflammatory drug is used, such as indomethacin, ibuprofen, tolmetin, phenylbutazone, ketoprofen, or other nonsteroidal anti -inflammatory drug, or a combination of nonsteroidal anti -inflammatory drugs.
Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it is obvious that certain modifications and changes can be practiced within the scope of the appended claims .
Claims
1. A composition for relieving soft tissue pain consisting essentially of an anti -inflammatory drug and from about 1 percent to about 10 percent benzyl alcohol in a pharmaceutical formulation suitable for topical application.
2. The composition of claim 1 wherein the formulation is a cream.
3. The composition of claim 1 wherein the formulation is a gel .
4. The composition of claim 1 wherein the formulation is a solution.
5. The composition of claim 1 wherein said anti-inflammatory drug is a nonsteroidal anti-inflammatory drug.
6. The composition of claim 5 wherein said nonsteroidal anti -inflammatory drug is piroxicam.
7. The composition of claim 6 wherein the concentration of piroxicam is between 0.1 percent to about 2 percent.
8. A method of treating soft tissue pain comprising applying a topical formulation consisting essentially of an anti-inflammatory drug and from about 1 percent to about 10 percent benzyl alcohol.
9. The method of claim 8 wherein said anti -inflammatory drug is a nonsteroidal anti -inflammatory drug.
10. The method of claim 8 wherein said formulation is a solution.
11. The method of claim 8 wherein said formulation is a gel.
SUBSTITUTE SHEET'(RULE 26)
12. The method of claim 8 wherein said formulation is a cream.
13. The method of claim 8 wherein said anti-inflammatory drug is piroxicam.
14. The method of claim 13 wherein the concentration of said
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU55232/98A AU5523298A (en) | 1996-12-20 | 1997-12-11 | Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77127196A | 1996-12-20 | 1996-12-20 | |
| US08/771,271 | 1996-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998027968A1 true WO1998027968A1 (en) | 1998-07-02 |
Family
ID=25091273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/022826 WO1998027968A1 (en) | 1996-12-20 | 1997-12-11 | Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5523298A (en) |
| WO (1) | WO1998027968A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100485A1 (en) * | 2005-03-24 | 2006-09-28 | Transphase Limited | A topical composition and its uses |
| JP2008534483A (en) * | 2005-03-24 | 2008-08-28 | トランスフェイズ・リミテッド | Transdermal topical composition and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867528A (en) * | 1973-10-11 | 1975-02-18 | American Cyanamid Co | Steroidal topical cream base |
| US4804541A (en) * | 1987-08-11 | 1989-02-14 | Moleculon, Inc. | Transdermal administration using benzyl alcohol |
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
-
1997
- 1997-12-11 WO PCT/US1997/022826 patent/WO1998027968A1/en active Application Filing
- 1997-12-11 AU AU55232/98A patent/AU5523298A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867528A (en) * | 1973-10-11 | 1975-02-18 | American Cyanamid Co | Steroidal topical cream base |
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| US4804541A (en) * | 1987-08-11 | 1989-02-14 | Moleculon, Inc. | Transdermal administration using benzyl alcohol |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100485A1 (en) * | 2005-03-24 | 2006-09-28 | Transphase Limited | A topical composition and its uses |
| JP2008534482A (en) * | 2005-03-24 | 2008-08-28 | トランスフェイズ・リミテッド | Topical compositions and uses thereof |
| JP2008534483A (en) * | 2005-03-24 | 2008-08-28 | トランスフェイズ・リミテッド | Transdermal topical composition and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5523298A (en) | 1998-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5560910A (en) | Topical anti-inflammatory composition and method | |
| EP0308210B1 (en) | Topical treatment of diseased skin disorders | |
| US5374661A (en) | Composition and method for transdermal delivery of diclofenac | |
| CN105142728B (en) | Compositions and methods for treating surface wounds | |
| US4555524A (en) | Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods | |
| US7052715B2 (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof | |
| HU211823A9 (en) | Formulations containing hyaluronic acid | |
| HU211689A9 (en) | Treatment of disease employing hyaluronic acid and nsaids | |
| WO2000009121A1 (en) | Anti-inflammatory analgesics | |
| JPH0147444B2 (en) | ||
| JP2012504624A (en) | Topical treatment of skin infections | |
| EP0055635A1 (en) | Pharmaceutical composition with acetylsalicylic acid in gel form | |
| US5278172A (en) | Method and composition for treating tendon or joint inflammation using a vasodilator | |
| JPH08505402A (en) | Method for treating mucosal epidermal and epidermal pain, inflammation and infectious disease and therapeutic composition | |
| WO1998027968A1 (en) | Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain | |
| US5128375A (en) | Keloid treating agent | |
| JP2860550B2 (en) | Acute skin inflammation treatment | |
| MICHELSON et al. | Treatment of cutaneous tuberculosis with large doses of vitamin D2 | |
| JPH0276816A (en) | External preparation | |
| JP3740701B2 (en) | Anti-inflammatory analgesic topical | |
| JP2006514072A (en) | Use of porphyrin synthetic substances for applications in phototherapy and for the treatment of skin and / or joint diseases | |
| Commandre et al. | Comparison of the analgesic and anti-inflammatory effects of topical niflumic acid gel versus piroxicam gel in the treatment of musculoskeletal disorders | |
| WO2001039725A2 (en) | Drug preparations | |
| RU2023444C1 (en) | Wound-healing agent for local application | |
| KR860000514B1 (en) | The method of forming a water soluble phenolphthalein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |